PRX003 is a monoclonal antibody under development by Prothena for the possible treatment of inflammatory diseases. It is currently being tested in patients with multiple sclerosis (MS).

Immune cells release cytokines that can trigger inflammation and are central to many inflammatory diseases. An MCAM (melanoma cell adhesion molecule) binds to a partner molecule the blood stream then then allows it to infiltrate adjacent tissues, leading to inflammation.

In healthy people, the blood-brain barrier prevents immune cells (lymphocytes) from entering the central nervous system. In people with MS, two types of lymphocytes, CD4 and CD8, find a way to cross the barrier. They then destroy the myelin sheath that protects neurons, resulting in brain lesions.

MCAM may play a crucial role in MS because it is necessary for the migration of both CD4 and CD8 lymphocytes across the blood-brain barrier. Blocking MCAM may delay the onset of MS and significantly slow its progression.

PRX003 binds to MCAM, blocks the route of inflammation, and prevents the migration of CD4 and CD8 lymphocytes into the brain tissue.

In March, Prothena completed a single ascending dose study of PRX003 in healthy participants (NCT02458677). All doses of PRX003 were reported as safe and tolerated following a single infusion up to 30 mg/kg dose. The results showed that PRX003 administration led to more than 95 percent MCAM neutralization.

Adverse effects reported were headache, balance disorder, seasonal allergies, and viral upper respiratory tract infection in 5 percent of participants.

A Phase 1b clinical study of PRX003 in people with psoriasis (NCT02630901) is ongoing.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

MS News That Caught My Eye Last Week: Early MS, Fenebrutinib, Restless Legs, Safer MRIs

Phase 4 Trial Will Test if Ocrevus Can Prevent MS Onset in RIS Patients Yes, you’re reading this right. This trial aims to see if Ocrevus can stop MS before it’s officially diagnosed — when it may be smoldering and presenting a minimum of MS-like activity. In July, this global trial is expected to begin […]

New 3D Model May Help in Promoting Myelin, Preventing Its Loss

A new 3D model of the human nervous system is meant to mimic key processes in the development of the myelin sheath — the fatty coating around nerve cells that is damaged in multiple sclerosis (MS) — to help with research into treatments that promote myelination. This model might also be useful in preventing demyelination, or […]

Lower Intestinal Fatty Acids May Contribute to MS in Women

Certain fat molecules produced by gut microbes, which have protective immune-suppressing effects and may protect against multiple sclerosis (MS), are lower in women than in men, a case-control study has found. These findings may explain the greater MS susceptibility observed in women, the scientists said. The study, “Short-chain fatty acids and intestinal inflammation in multiple sclerosis: […]

When in Doubt, Make a Mixtape

Spring is here, a time we’d normally be out and about getting some sun and recharging our souls after a long winter. I certainly look forward to working in the yard, hiking, having outdoor picnics, and taking the occasional road trip. But this isn’t a typical year, is it? We’re still dealing with COVID-19, and […]

Slipping Over the Event Horizon Into SPMS

Isn’t it just like me to start my column with a physics analogy that is already confusing? Please stick with me, as all will be revealed. My point is that if a black hole is big enough, you might slip through its event horizon without even noticing. There would be no way out. However, if […]

This New Tool Can Help You Choose Which DMT to Use

Sometimes it seems as if people with MS are asked to flip a coin to make what’s arguably the most important decision about their treatment: which disease-modifying therapy (DMT) to use. More than 20 DMTs are approved in the U.S., similar to what’s available in the rest of the world. DMTs are administered via pills, […]

Phase 4 Trial Will Test if Ocrevus Can Prevent MS Onset in RIS Patients

Yale University is launching CELLO, a multicenter study to investigate the efficacy of Ocrevus (ocrelizumab) in treating people with lesions suggestive of multiple sclerosis (MS), a condition known as radiologically isolated syndrome. The Phase 4 study (NCT04877457) aims to evaluate whether short-term treatment with Ocrevus can delay or prevent the onset of MS in radiologically isolated […]

Canada’s MS Walk Returns for Awareness Month

The Multiple Sclerosis Society of Canada‘s (MSSC) MS Walk fundraiser is still on for this month — May is MS Awareness Month in Canada — although in an altered form due to the pandemic. The annual nationwide community-driven event raises funds and MS awareness to help battle the neurodegenerative disorder. Since in-person MSSC events are out […]

Global Phase 3 Trials of Fenebrutinib Enrolling Relapsing and PPMS Patients

Two global Phase 3 clinical trials comparing fenebrutinib, an investigational oral BTK inhibitor by Roche, with Aubagio (teriflunomide) are now enrolling adults with relapsing forms of multiple sclerosis (MS), the National MS Society announced in a press release. The twin studies, called FENhance 1 (NCT04586023) and FENhance 2 (NCT04586010), aim to enroll a total of 1,468 adults, […]